Latest Headlines

Latest Headlines

Bristol-Myers to buy Medarex for $2.1B

Anxious to beef up its pipeline, Bristol-Myers Squibb announced late Wednesday that it had struck a deal to buy Medarex for $2.4 billion. But the dealmakers note that the $300 million on Medarex's

Medarex shares rise on surprising cancer study

Shares of Medarex shot up 17 percent after investigators at the Mayo Clinic say they were startled by the level of success seen in a trial of a monoclonal antibody for prostate cancer. Two of the men

Medarex shares dented on analysts' skepticism

Investors dented the value of Medarex shares after analysts doused its recent claims concerning its late-stage cancer drug ipilimumab with cold water. BMO Capital Market's Jason Zhang says that

Medarex shares slide on news of drug app delay

Shares of Medarex slipped seven percent this morning as investors digested Friday's announcement that its application for a new cancer drug will be delayed into 2009. The developer says that the FDA